Why the study?
suPAR is a marker of immune activation and inflammation that may provide diagnostic value on top of established biomarkers in patients with suspected AMI.
Does adding suPAR to high-sensitivity troponin I improve the early diagnosis of acute myocardial infarction in patients presenting to the emergency department?
Does adding suPAR to high-sensitivity troponin I improve the early diagnosis of acute myocardial infarction in patients presenting to the emergency department?
Circulating levels of suPAR do not improve the early diagnosis of acute myocardial infarction when added to high-sensitivity troponin I.
No takes yet. Share an insight, caveat, or question.
May support suPAR as adjunct to hs-TnI for suspected AMI diagnosis; hypothesis-generating and requires prospective validation.
Sörensen et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: